NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

Fisher HealthCare, which is part of Thermo Fisher Scientific, will distribute Response Bio's Infectious Disease Point of Care test panel, which includes the Ramp Flu A + B test and the Ramp RSV test. The assays run on the firm's Ramp 200 system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.